Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S9.72
P/E—
Fwd P/E-13.03
PEGN/A
52W— – —
RSI—
Target$49.37 (-9.4%)
Beta0.94
Div—
Loading chart…
RSI (14)
Loading patterns…
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 38
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
2Bullish
0Bearish
0Neutral
▲ Double Bottom — Two lows ~$44.76 — bullish reversal confirmed
▲ Inv. Head & Shoulders — Inv. H&S neckline ~$57.84 broken — major bullish reversal
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
88%
7/8 quarters
Wall Street Consensus
HOLD
BuyHoldSell
Price Target Range
$49.37
-9.4% upside
Low $25
—
High $79
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Goldman Sachs | Neutral | — | ↔ Maintain | 2026-07-21 |
| Morgan Stanley | Equal-Weight | — | ↔ Maintain | 2026-07-08 |
| RBC Capital | Sector Perform | — | ↔ Maintain | 2026-07-07 |
| B of A Securities | Underperform | — | ↔ Maintain | 2026-07-07 |
| Piper Sandler | Overweight | — | ↔ Maintain | 2026-06-26 |
| UBS | Neutral | — | ↔ Maintain | 2026-05-04 |
| Evercore ISI Group | In-Line | — | ↔ Maintain | 2026-05-04 |
| Barclays | Equal-Weight | — | ↔ Maintain | 2026-04-02 |
| Jefferies | Hold | — | ● Initiate | 2025-12-12 |
| Leerink Partners | Underperform | — | ↔ Maintain | 2025-11-21 |
Goldman Sachs
2026-07-21
Neutral
↔ Maintain
Morgan Stanley
2026-07-08
Equal-Weight
↔ Maintain
RBC Capital
2026-07-07
Sector Perform
↔ Maintain
B of A Securities
2026-07-07
Underperform
↔ Maintain
Piper Sandler
2026-06-26
Overweight
↔ Maintain
UBS
2026-05-04
Neutral
↔ Maintain
Evercore ISI Group
2026-05-04
In-Line
↔ Maintain
Barclays
2026-04-02
Equal-Weight
↔ Maintain
Jefferies
2025-12-12
Hold
● Initiate
Leerink Partners
2025-11-21
Underperform
↔ Maintain
Profitability
Gross Margin
-69.89%TTM
Op. Margin
-131.10%TTM
ROE
-36.56%TTM
Rev. Growth
260.20%YoY
Free Cash Flow
-20.00MTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
17.52MRQ
Current Ratio
2.41MRQ
Cash
5.21BMRQ
Total Debt
1.30BMRQ
Net Debt
—MRQ
How MRNA Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 21.62B |
| Enterprise Value | 17.71B |
| Trailing P/E | N/A |
| Forward P/E | -13.03 |
| PEG Ratio (5yr) | N/A |
| Price/Sales (ttm) | 9.72 |
| Price/Book (mrq) | 2.92 |
| EV/Revenue | 7.96 |
| EV/EBITDA | -7.71 |
Share Statistics
| Avg Vol (3m) | 7.73M |
| Shares Outstanding | 396.79M |
| Float | 370.06M |
| % Held by Insiders | 7.31% |
| % Held by Institutions | 78.32% |
| Short Ratio | 5.21 |
| Short % of Float | 16.15% |
Profitability
| Gross Margin | -69.89% |
| Operating Margin (ttm) | -131.10% |
| Profit Margin | -143.55% |
| Return on Assets (ttm) | -13.09% |
| Return on Equity (ttm) | -36.56% |
Income Statement
| Revenue (ttm) | 2.22B |
| Revenue Growth (yoy) | 260.20% |
| Gross Profit (ttm) | -1.56B |
| EBITDA | -2.30B |
| Net Income (ttm) | -3.19B |
| Diluted EPS (ttm) | -7.95 |
| EPS Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 5.21B |
| Total Debt (mrq) | 1.30B |
| Debt / Equity (mrq) | 17.52 |
| Current Ratio (mrq) | 2.41 |
| Book Value / Share | 18.66 |
| Operating CF (ttm) | -1.47B |
| Free Cash Flow (ttm) | -20.00M |
Trading & Dividends
| Beta (5Y) | 0.94 |
| 50-Day MA | 58.03 |
| 200-Day MA | 44.56 |
| Fwd Dividend Yield | N/A |
| Payout Ratio | 0.00% |
Ownership Breakdown
Institutional 78.32%
Insider 7.31%
Public 14.4%
Short Interest
16.15% of float
High
Institutional 13F Holdings
Famous investors who disclosed a position in MRNA in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-15 | HOGE STEPHEN | President | Conversion of Exercise of derivative security at price 19.15 per share. | 53,336 | $1,021,384 |
| 2026-07-15 | HOGE STEPHEN | President | Sale at price 67.60 per share. | 53,336 | $3,605,514 |
| 2026-07-02 | MOCK JAMES M | Chief Financial Officer | 1,452 | — | |
| 2026-06-15 | HOGE STEPHEN | President | Conversion of Exercise of derivative security at price 19.15 per share. | 53,336 | $1,021,384 |
| 2026-06-15 | HOGE STEPHEN | President | Sale at price 51.37 per share. | 53,336 | $2,739,870 |
| 2026-06-05 | KLINGER SHANNON THYME | Officer | Conversion of Exercise of derivative security at price 30.96 per share. | 15,269 | $107,462 |
| 2026-06-05 | MOCK JAMES M | Chief Financial Officer | 11,798 | — | |
| 2026-06-04 | KLINGER SHANNON THYME | Officer | Sale at price 50.00 per share. | 3,471 | $173,550 |
| 2026-06-01 | KLINGER SHANNON THYME | Officer | 2,165 | — | |
| 2026-06-01 | MOCK JAMES M | Chief Financial Officer | 2,475 | — | |
| 2026-06-01 | HOGE STEPHEN | President | 9,282 | — | |
| 2026-05-28 | KLINGER SHANNON THYME | Officer | 1,101 | — | |
| 2026-05-28 | MOCK JAMES M | Chief Financial Officer | 1,101 | — | |
| 2026-05-28 | HOGE STEPHEN | President | 2,047 | — | |
| 2026-05-21 | AFEYAN NOUBAR BOGHOS | Director | Conversion of Exercise of derivative security at price 19.15 per share. | 9,263 | $177,386 |
| 2026-05-21 | AFEYAN NOUBAR BOGHOS | Director | Sale at price 46.84 per share. | 9,263 | $433,879 |
| 2026-05-15 | HOGE STEPHEN | President | Conversion of Exercise of derivative security at price 19.15 per share. | 53,336 | $1,021,384 |
| 2026-05-15 | HOGE STEPHEN | President | Sale at price 48.40 per share. | 53,336 | $2,581,462 |
| 2026-05-01 | HUSSAIN SHAH ABBAS | Director | Sale at price 46.63 per share. | 5,682 | $264,952 |
| 2026-04-30 | HUSSAIN SHAH ABBAS | Director | 16,233 | — | |
| 2026-04-30 | TALLETT ELIZABETH E | Director | 4,058 | — | |
| 2026-04-30 | RUBENSTEIN DAVID M | Director | 8,116 | — | |
| 2026-04-30 | NABEL ELIZABETH G | Director | 16,233 | — | |
| 2026-04-30 | HORNING SANDRA | Director | 16,233 | — | |
| 2026-04-30 | NADER FRANCOIS E. | Director | 12,174 | — |
HOGE STEPHEN
President
Conversion of Exercise of derivative security at price 19.15 per share.
2026-07-15
53,336 sh
$1,021,384
HOGE STEPHEN
President
Sale at price 67.60 per share.
2026-07-15
53,336 sh
$3,605,514
MOCK JAMES M
Chief Financial Officer
2026-07-02
1,452 sh
—
HOGE STEPHEN
President
Conversion of Exercise of derivative security at price 19.15 per share.
2026-06-15
53,336 sh
$1,021,384
HOGE STEPHEN
President
Sale at price 51.37 per share.
2026-06-15
53,336 sh
$2,739,870
KLINGER SHANNON THYME
Officer
Conversion of Exercise of derivative security at price 30.96 per share.
2026-06-05
15,269 sh
$107,462
MOCK JAMES M
Chief Financial Officer
2026-06-05
11,798 sh
—
KLINGER SHANNON THYME
Officer
Sale at price 50.00 per share.
2026-06-04
3,471 sh
$173,550
KLINGER SHANNON THYME
Officer
2026-06-01
2,165 sh
—
MOCK JAMES M
Chief Financial Officer
2026-06-01
2,475 sh
—
HOGE STEPHEN
President
2026-06-01
9,282 sh
—
KLINGER SHANNON THYME
Officer
2026-05-28
1,101 sh
—
MOCK JAMES M
Chief Financial Officer
2026-05-28
1,101 sh
—
HOGE STEPHEN
President
2026-05-28
2,047 sh
—
AFEYAN NOUBAR BOGHOS
Director
Conversion of Exercise of derivative security at price 19.15 per share.
2026-05-21
9,263 sh
$177,386
AFEYAN NOUBAR BOGHOS
Director
Sale at price 46.84 per share.
2026-05-21
9,263 sh
$433,879
HOGE STEPHEN
President
Conversion of Exercise of derivative security at price 19.15 per share.
2026-05-15
53,336 sh
$1,021,384
HOGE STEPHEN
President
Sale at price 48.40 per share.
2026-05-15
53,336 sh
$2,581,462
HUSSAIN SHAH ABBAS
Director
Sale at price 46.63 per share.
2026-05-01
5,682 sh
$264,952
HUSSAIN SHAH ABBAS
Director
2026-04-30
16,233 sh
—
TALLETT ELIZABETH E
Director
2026-04-30
4,058 sh
—
RUBENSTEIN DAVID M
Director
2026-04-30
8,116 sh
—
NABEL ELIZABETH G
Director
2026-04-30
16,233 sh
—
HORNING SANDRA
Director
2026-04-30
16,233 sh
—
NADER FRANCOIS E.
Director
2026-04-30
12,174 sh
—